Mi et al. discover that LKB1 deficiency creates a hypomorphic PRMT5 state in lung cancer via NNMT-mediated “methyl sink.” Targeting PRMT5 triggers senescence in LKB1-deficient cancer cells and confers vulnerability to senolytics such as Navitoclax, representing an effective combination cancer therapy.